TTY Biopharm Suspected of Inside Trading|疫苗案東洋股票量價波動大 涉內線交易?
加入公視會員，
按讚收藏你關注的報導
發布時間：
更新時間：
TTY Biopharm claimed it was the potential distributor of the vaccine but now it is reported that its negotiation with the developer has failed. Some have speculated that TTY Biopharm used the potential deal as a tool to boost its stock prices.
(Will you suggest the Financial Supervisory Commission to look into this?) CECC will not make such a suggestion, that's for the FSC to decide.
TTY Biopharm Company has failed to reach a deal with Germany's BioNTech SE to distribute its COVID-19 vaccines because the company couldn't provide a formal authorization and a draft contract. However, some have suspected the potential deal has been used to fraudulently inflate the company's stock prices. When asked about the news, CECC Commander Chen Shih-chung said he believed the statement from TTY Biopharm was not exaggerated but it was up to the Financial Supervisory Commission (FSC) to look into the matter. A number of Kuomintang lawmakers in the Legislative Finance Committee urged the FSC to conduct a thorough investigation.
The trading volume of TTY Biopharm's stock skyrocketed to more than 30,000 then it plummeted to a very low volume. I believe that someone is behind this. That graph of trading volume does look suspicious.
The stock price slumped by 2.4 percent on November 3, the day before the company announced the failure to reach an agreement. Then the price drop sharply to hit the limit down on the second day. We will handle the issue according to the law.
Investors trusted TTY Biopharm completely as its Chairperson, former Premier Lin Chuan, made the authorization of distribution announcement himself. The stock price rose from NT$66.5 per share at the end of September, all the way up to NT$69.5 per share on October 12 after the company announced the right to distribute the vaccines. On October 13, the closing price was NT$76.4 per share, which surged to NT$84 on the 14th and the 15th. After the company announced the failure of the deal on November 3, the stock price plummeted to the lower limit on the 4th with a closing price of NT$69.3 per share on the 9th.
It is suspected that the details of the contract announced by TTY Biopharm were incongruent with what was negotiated with BNT. In addition to that, there was an abnormal huge amount of trading of TTY Biopharm's stocks before and after the announcement. The CECC, in response, said it will cooperate with the FSC on providing related information.
We fully respect FSC's power and responsibility. We will cooperate with the FSC and provide them with information related to the deal.
TTY Biopharm issued a statement, urging the public not to deliberately spread rumors to discredit the company on issues related to the BNT vaccines. The company said it reserves the right to take legal actions as a resort to protect the company's reputation and stockholder's rights. The FSC stressed that the result of its investigation will be out in two weeks.
The Commission will also investigate whether the company has violated Article 157 of the Securities and Exchange Act and committed insider trading. The audit is expected to be completed within two months.
中央流行疫情指揮中心指揮官 陳時中 (109.11.4)表示：「（會建議金管會去調查嗎？) 我們不建議，那是金管會的事情。」
台灣東洋代理德國新冠肺炎疫苗宣布破局，原因為台灣東洋無法提供正式授權書及合約草案，被外界質疑是要藉機炒股，日前中央流行疫情指揮中心指揮官陳時中表示金管會可以查，但東洋發布的消息沒有誇大不實，多位國民黨立委在立法院財政委員會表示，東洋這段時間股價及成交量異常，疑似有內線交易，要求金管會徹查。
金管會主委 黃天牧 vs. 國民黨立委 費鴻泰表示：「（台灣東洋)股市飆到…最高飆到3萬多張，後來就一路下滑，量就變得小，你說沒有人在搞鬼？我是不相信。(那個(成交量)圖看起來，是有可疑之處。)」
金管會主委 黃天牧 vs. 國民黨立委 賴士葆表示：「11月3號，它開(代理破局)記者會之前，那一天是爆量下跌，跌了2.4%。當然第2天，就全部跌停了。(我們都秉公依法辦理。)」
事實上在前行政院長林全帶頭宣告下，投資人給予東洋完全的信任與信心，股價從9月底的收盤價66.5元，飆到10月12號的69.5元，發布代理疫苗重大訊息後，10月13號收盤價來到76.4元，14、15號收盤更飆升到84元，11月3號宣布代理破局，4號股價即跳空跌停，9號的收盤價為69.3元。針對台灣東洋記者會公布與德國BNT合作內容與訊息不一，且前後股票有大量異常交易，指揮中心也表示將會配合金管會提供諮商所需相關資料。
中央流行疫情指揮中心醫療整備組副組長 羅一鈞表示：「全權尊重金管會的權責。金管會跟我們索取，什麼相關磋商當中的資料，我們都會配合提供。」
而台灣東洋則發出新聞稿表示，有關BNT疫苗的諸多不實指控，企盼外界勿再刻意造謠抹黑、以不實言論以訛傳訛，台灣東洋為維護企業聲譽以及股東權益，將保留法律追訴權以正視聽。金管會強調，台灣東洋的重大訊息公告是否符合規定，2週內會有結果。另外，也將追查違反證交法第157條，有無內線交易問題，預計2個月內會查核完畢。
